title: Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
abstract: BACKGROUND
  Cytokines are major contributors in the immune disruption in multiple sclerosis (MS).
  
  
  OBJECTIVE
  Evaluating the proinflammatory (IL-17A) and anti-inflammatory (IL-10) cytokines in relapsing-remitting (RR) MS patients at time of relapse and during remission.
  
  
  METHODS
  A case-control study including 30 RRMS patients and 15 controls. Patients were recruited from the Kasr Al-Ainy MS research unit (KAMSU), Cairo University, Egypt. Levels of IL-17A and IL-10 were assessed in patients' sera, during relapse and 30days after IV methylprednisolone, and in control subjects using enzyme linked immunosorbent assays (ELISA).
  
  
  RESULTS
  IL-17 was higher in patients during relapse and remission phases when compared with controls (P=0.001), whereas, IL-10 was higher in patients during remission but normal during relapse (P=0.01; 0.86 respectively). IL-17 increased during relapses (P=0.001) while IL-10 increased during remissions (P=0.028). No significant correlations were found between both interleukins and age at onset; disease duration, number of relapses; or EDSS.
  
  
  CONCLUSIONS
  RRMS patients can have a regulatory imbalance between both pro-and antiinflammatory cytokines, which could be a target for treatment strategies rather than focusing on a single cytokine.
authors.affiliation: Faculty of Medicine, Cairo University, Egypt.
authors.forename: Tarek Z
authors.initials: TZ
authors.lastname: Tawfik
authors.affiliation: Faculty of Medicine, Cairo University, Egypt.
authors.forename: Adel H
authors.initials: AH
authors.lastname: Gad
authors.affiliation: Faculty of Medicine, Cairo University, Egypt.
authors.forename: Dina A
authors.initials: DA
authors.lastname: Mehaney
authors.affiliation: Faculty of Science, Suez University, Egypt.
authors.forename: Eslam
authors.initials: E
authors.lastname: El Nahrery
authors.affiliation: Faculty of Medicine, Cairo University, Egypt.
authors.forename: Hatem S
authors.initials: HS
authors.lastname: Shehata
authors.affiliation: National Research Center (NRC), Cairo, Egypt.
authors.forename: Hebatalla
authors.initials: H
authors.lastname: Hashem
authors.affiliation: Faculty of Medicine, Cairo University, Egypt.
authors.forename: Nawal F Abdel
authors.initials: NFA
authors.lastname: Ghaffar
authors.affiliation: Faculty of Medicine, Cairo University, Egypt. Electronic address: nevinmohy@gmail.com.
authors.forename: Nevin
authors.initials: N
authors.lastname: Shalaby
mesh_terms: D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D004185:Disability Evaluation; D004534:Egypt; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D020381:Interleukin-17 / Q000097:blood*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000188:drug therapy; D018709:Statistics, Nonparametric; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D020381:Interleukin-17; D016753:Interleukin-10; D008775:Methylprednisolone
keywords: Egyptian; IL-10; IL-17; Relapsing remitting multiple sclerosis